Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma

Nawata, Sumihiko; Abecasis, Nuno; Ross, Howard M.; Abolhoda, Amir; Cheng, Hongyan; Sachar, Komal S.; Burt, Michael

doi:10.1016/s0022-5223(96)70013-2

Cited by 30 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we observed a 33% (2/6) rate of complete long-term response in the melphalan-perfused rats, with no evidence of disease up to 3 months after ILuP. These results are in line with previous studies of melphalan in which ILuP with melphalan was superior to intravenous treatment protocols [2,12]. In conclusion, clinical phase I studies evaluating ILuP for the treatment of lung metastases need to be done.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Isolated Lung Perfusion with Melphalan Prolongs Survival in a Rat Model of Metastatic Pulmonary Adenocarcinoma

Hendriks

Schil²,

Oosterom³

et al. 1999

Eur Surg Res

View full text Add to dashboard Cite

Introduction: Survival after isolated lung perfusion (ILuP) with melphalan was tested in a model of unilateral pulmonary adenocarcinoma. Methods: On day 0, rats were randomized into four groups: Group 1 (n = 9) reveived tumor cells intravenously for induction of bilateral lung metastases, whereas groups 2–4 (n = 21) underwent a 10-min occlusion of the right pulmonary artery during tumor cell injection for induction of unilateral left lung metastases. On day 7, groups 1 and 2 received no treatment. Group 3 underwent left ILuP with melphalan (2.0 mg/kg) while group 4 received melphalan intravenously (0.5 mg/kg). The end point of the study was death from metastatic disease. Results: Median survival of ILuP-treated animals (81 ± 12 days) was significantly longer compared to group 1 (18 ± 1 days; p = 0.0001), group 2 (28 ± 3 days; p = 0.0002) and group 4 (37 ± 6; p = 0.0004). Conclusions: ILuP with melphalan prolongs survival in the treatment of experimental metastatic pulmonary carcinoma.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Several tumor cell lines implanted in rodents allowed us to conduct efficacy experiments using various chemotherapeutic and biological agents in ILuP models [9][10][11][12][13]. We primarily used a dimethylhydrazine-induced adenocarcinoma cell line for the establishment of pulmonary metastases.…”

Section: Discussionmentioning

confidence: 99%

Isolated Lung Perfusion with Melphalan Prolongs Survival in a Rat Model of Metastatic Pulmonary Adenocarcinoma

Hendriks

Schil²,

Oosterom³

et al. 1999

Eur Surg Res

View full text Add to dashboard Cite

show abstract

“…Therefore, melphalan is also investigated in the setting of ILuP for both carcinoma and sarcoma lung metastases. Nawata et al showed in 1996 that melphalan was effective in eliminating sarcoma lung metastases in a rodent model, but no survival data were published (156). This effect was confirmed by a study from our own institution in a rodent model with metastatic rhabdomyosarcoma.…”

Section: Melphalanmentioning

confidence: 81%

Lung Metastatic Disease: Surgical Resection and Locoregional Chemotherapy

Hengst¹,

Hendriks²,

Schil³

2012

Toraks Cer Bult

View full text Add to dashboard Cite

Currently, surgical resection remains the gold standard for resectable lung metastases. Prognostic factors are histology, complete resection, number of metastases and disease-free interval. However, there is a high rate of recurrent disease in the thorax, even if systemic chemotherapy is applied. Because the latter is limited in dose due to systemic toxicity, new treatment options are being developed to selectively deliver high-dose chemotherapy into the lung, reducing systemic toxicity. Isolated lung perfusion (ILuP), similar to isolated limb perfusion, is an experimental surgical technique to deliver highdose chemotherapy into the lung without systemic exposure. Biological response modifiers like tumour necrosis factor can also be administered. ILuP results in significantly higher concentration of chemotherapy in the target organ compared to systemic chemotherapy, together with a survival benefit in experimental models of pulmonary metastases. Several phase I studies have shown that ILuP is technically feasible with low morbidity and low impact on the patient's pulmonary function. However, the utility of this technique is limited because it is an invasive technique. Other techniques to selectively deliver high-dose locoregional chemotherapy are embolic trapping (chemo-embolization), selective pulmonary artery perfusion (SPAP) without control of the venous effluent and the minimally invasive lung suffusion technique. This review will discuss surgical resection of lung metastases and address several techniques developed to deliver high doses of chemotherapy into the lung, as well as the current progress in experimental and clinical studies.

show abstract

“…Intravenous therapy as compared with isolated lung perfusion is inferior in its tumor-reducing effect, both confirmed for carcinoma and sarcoma models [6,8].…”

Section: Introductionmentioning

confidence: 85%

Variations in Flow, Duration, and Concentration Do Not Change the Final Lung Concentration of Melphalan after Isolated Lung Perfusion in Rats

et al. 2003

View full text Add to dashboard Cite

Objective: The influences of flow, perfusion time, and concentration on melphalan (MN) lung levels in a rat model of isolated lung perfusion (ILuP) were studied. Methods: ILuP was performed in WAG/Rij rats by using a single-pass system with 0.5, 0.05, 0.01, and 0.005 mg of MN. Subsequently ILuP with 0.05 mg MN was performed during 30 min with a flow rate of 0.5 ml/min, during 60 min with a flow rate of 0.5 ml/min, and during 30 min with a flow rate of 1.0 ml/min. Results: The lung MN levels of 0.05 mg were significantly lower as compared with 0.5 mg (p = 0.02). In the second experiment, no significant differences were seen in lung levels of MN between the different groups. Conclusion: The final lung MN levels were only determined by the absolute amount administered.

show abstract

Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma

Abstract: Isolated lung perfusion with melphalan is safe and effective in the treatment of pulmonary sarcoma metastases in the rat.

Cited by 30 publications

References 21 publications

Isolated Lung Perfusion with Melphalan Prolongs Survival in a Rat Model of Metastatic Pulmonary Adenocarcinoma

Isolated Lung Perfusion with Melphalan Prolongs Survival in a Rat Model of Metastatic Pulmonary Adenocarcinoma

Lung Metastatic Disease: Surgical Resection and Locoregional Chemotherapy

Variations in Flow, Duration, and Concentration Do Not Change the Final Lung Concentration of Melphalan after Isolated Lung Perfusion in Rats

Contact Info

Product

Resources

About